H

Hospital La Arruzafa | Cordoba, Spain

Research site

(Unclaimed)

Location

Avenida de la Arruzafa 9, Córdoba, Córdoba, Spain

Site insights

Top conditions

Top treatments

VRDN-001

Zimura

Teprotumumab

VRDN 001

Ripasudil

GT005

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 11 total trials

A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( THRIVE )

Please note that Phase 1/2 (HV \&amp;amp ; TED MAD) cohorts and Phase 3 component (THRIVE) - recruitment is complete.The investigational drug, ve...

Active, not recruiting

Thyroid Eye Disease

Drug: Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED)

Drug: VRDN-001 Placebo

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Enrolling

Fuchs Endothelial Corneal Dystrophy

Drug: Ripasudil

Drug: Placebo

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) (THRIVE-2)

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chr...

Active, not recruiting

Thyroid Eye Disease

Drug: Veligrotug (VRDN-001)

Drug: Placebo

Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. (CELOPHIN)

A phase IIa, open label, non controlled clinical trial to assess the feasibility and safety of allogeneic adipose-derived mesenchymal stem cells (ASC...

Active, not recruiting

Pemphigoid

Lyell Syndrome

Drug: Double Dose

Drug: Single Dose

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of...

Active, not recruiting

Thyroid Eye Disease

Drug: Teprotumumab

Drug: Placebo